BIOMAT Database Logo BIOMAT Database Logo

Posttransplant oral iron-chelating therapy in patients with beta-thalassemia major. 2010

M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
Department of Pediatric Hematology-Oncology, Akdeniz University School of Medicine, Antalya, Turkey.

Allogeneic hematopoetic stem cell transplantation (HSCT) is the only radical cure of beta-thalassemia. However, iron overload remains a cause of morbidity and mortality in posttransplant period. The authors present 7 patients as a preliminary report who underwent bone marrow transplant (BMT) and received oral chelating therapy (deferasirox) because of poor compliance to phlebotomy and desferrioxamine. The patients investigated mainly for possible side effects of deferasirox. No negative effect was seen in aspartate aminotransferase (AST), alanine aminotransferase (ALT), hemoglobin (Hb), and donor chimerism of the patients while serum ferritin levels significantly reduced (P = .018). Although serum creatinin significantly increased (P = .034), it was in normal limits in all patients. The authors believe that this report shows promising findings to plan further studies to clarify clinical safety and efficacy of deferasirox in posttransplant period.

UI MeSH Term Description Entries
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003401 Creatine An amino acid that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as CREATININE in the urine.
D005260 Female Females
D005293 Ferritins Iron-containing proteins that are widely distributed in animals, plants, and microorganisms. Their major function is to store IRON in a nontoxic bioavailable form. Each ferritin molecule consists of ferric iron in a hollow protein shell (APOFERRITINS) made of 24 subunits of various sequences depending on the species and tissue types. Basic Isoferritin,Ferritin,Isoferritin,Isoferritin, Basic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077588 Deferasirox A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA. 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid,Exjade,ICL 670,ICL 670A,ICL-670,ICL-670A,ICL670,ICL670A
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
Agranulocyosis in Beta Thalassemia Major Patients treated with Oral Iron Chelating Agent (Deferiprone).
October 2008, Oman medical journal,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
[Patient compliance in iron-chelating therapy of beta-thalassemia major].
May 1983, Minerva pediatrica,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
[Hypertransfusion, chelating and immunocorrective therapy in beta-thalassemia major].
January 1987, Pediatriia,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
Iron-chelation therapy with oral chelators in patients with thalassemia major.
January 2013, Hematology (Amsterdam, Netherlands),
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
Oral iron chelation therapy with deferiprone in patients with Thalassemia Major.
June 2009, JPMA. The Journal of the Pakistan Medical Association,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
Iron-chelation therapy with oral deferiprone in patients with thalassemia major.
April 1995, The New England journal of medicine,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia.
January 2000, Journal of pediatric hematology/oncology,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
Intensification of chelating-therapy in patients with thalassemia major.
January 2005, Klinische Padiatrie,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
[Thalassemia major: chelating therapy with deferoxamine].
January 1985, Medicina,
M Akif Yesilipek, and Gulsun Karasu, and Mediha Kazik, and Vedat Uygun, and Zeynep Ozturk
[Chelating therapy in beta-thalassemia].
January 1982, La Pediatria medica e chirurgica : Medical and surgical pediatrics,
Copied contents to your clipboard!